New guidance from the American College of Cardiology elevates chronic inflammation to a core focus of cardiovascular prevention, reshaping decades of cholesterol-centered practice.
By yourNEWS Media Newsroom
For decades, heart disease prevention in the United States has revolved around a single laboratory number: cholesterol. Patients were routinely told that lowering LDL cholesterol was the primary defense against heart attacks and strokes, often leaving clinical visits with statin prescriptions and little discussion of deeper biological processes. A new scientific statement from the American College of Cardiology signals a fundamental shift away from that narrow framework, placing chronic inflammation at the center of cardiovascular risk assessment and treatment.
The 2025 ACC scientific statement calls for routine screening of systemic inflammation using the high-sensitivity C-reactive protein test in both primary and secondary prevention. The guidance reflects a growing consensus that inflammation is not a side effect of atherosclerosis but a driving force behind it, influencing whether arterial plaque remains stable or progresses to rupture and thrombosis.
The ACC concluded that decades of research demonstrate inflammation is often a stronger predictor of future heart attacks and strokes than LDL cholesterol, even among patients who have achieved very low cholesterol levels with medication. This helps explain why many individuals who appear well-controlled on lipid panels still suffer cardiovascular events, a phenomenon researchers describe as “residual inflammatory risk.”
Large population studies underpin the shift. In one long-term analysis tracking nearly 28,000 initially healthy women for 30 years, a single measurement of high-sensitivity C-reactive protein predicted cardiovascular events across the full follow-up period more powerfully than LDL cholesterol. Similar findings emerged in contemporary clinical trials involving more than 31,000 statin-treated patients, where elevated inflammatory markers proved more predictive of heart attack, stroke, or cardiovascular death than cholesterol levels.
Registry data reinforce the pattern. In a Swedish cohort of more than 84,000 patients with established atherosclerotic disease receiving modern care, roughly 60 percent continued to show elevated inflammatory markers and experienced worse outcomes despite cholesterol management. Researchers concluded that in these patients, the biological process driving disease progression remained active even as lipid levels were controlled.
The scientific rationale is rooted in the biology of atherosclerosis. Rather than a passive accumulation of fat within arteries, the disease is now understood as an inflammatory condition. Chronic, low-grade inflammation damages the endothelial lining of blood vessels, triggering immune responses that draw white blood cells into the arterial wall. These cells ingest cholesterol and form early plaque structures that remain metabolically active. Ongoing inflammation weakens the plaque’s protective cap, increasing the risk of rupture. When rupture occurs, clot formation can abruptly block blood flow, resulting in heart attack or stroke. In this sequence, cholesterol contributes to plaque formation, but inflammation initiates and accelerates the process.
The ACC statement emphasizes that effective prevention requires measurement. As the document states, “Clinicians will not treat what they do not measure.” It recommends routine assessment of inflammatory status, noting that levels below 1 mg/L indicate lower cardiovascular risk, 1 to 3 mg/L reflect average risk, and values above 3 mg/L signify higher risk independent of cholesterol levels.
Treatment strategies outlined in the guidance prioritize lifestyle interventions as the foundation of inflammation control. Dietary patterns rich in plant compounds, unsaturated fats, and omega-3 fatty acids, such as the Mediterranean diet, are highlighted for their ability to reduce cardiovascular events by dampening inflammatory pathways. Regular physical activity and smoking cessation are also identified as powerful anti-inflammatory measures.
For patients with established cardiovascular disease who continue to show elevated inflammatory markers despite optimal cholesterol therapy, the ACC recognizes the role of targeted pharmacologic intervention. Low-dose colchicine, an inexpensive anti-inflammatory medication, has demonstrated meaningful reductions in recurrent cardiovascular events in large clinical trials and is now recognized as an option for high-risk patients. The statement also notes ongoing research into more selective biologic therapies aimed at specific inflammatory pathways.
The new guidance resolves a long-standing debate within cardiology. For years, researchers observed inconsistencies between cholesterol levels and disease severity, as well as cardiovascular benefits from dietary and lifestyle interventions that did not significantly lower lipids. Evidence that statins themselves exert anti-inflammatory effects further complicated the cholesterol-only model.
Rather than abandoning cholesterol management, the ACC places it within a broader biological framework. The statement affirms that lipid lowering remains important but is insufficient on its own for many patients. Addressing inflammation directly, the college concluded, is essential to reducing cardiovascular risk and improving outcomes.
The updated approach offers a more comprehensive explanation for why heart disease risk varies widely between individuals and provides clinicians with additional tools to intervene earlier and more effectively. By shifting from a mechanical view of blocked arteries to a biological understanding of vascular injury and immune response, the ACC’s guidance marks a significant evolution in how cardiovascular disease is prevented and treated.
Source: Natural News
Original article
Comments